Rigel Pharma (RIGL) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.78 +1.47%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $4.01 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
